Theriva approves stock plan increase through 2026 amendment
The Board of Theriva Biologics authorized a proposal to amend its 2020 Stock Incentive Plan by increasing the available shares by 2 million to 6.5 million. If approved, this will authorize additional grants of Awards under the Plan.
View filing at SEC.gov →